NCT04334668Active, not recruiting
Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure
Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure (OSPREY-AHF)
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The investigators are proposing a prospective, randomized, double blinded, placebo-controlled single center study evaluating the role of co-administration of oral sodium chloride (NaCl) with intravenous diuretics in patients hospitalized with acute decompensated heart failure. The investigators are approaching this study with the hypothesis that the use of oral sodium chloride leads to improved effective diuresis (as measured by weight loss) and renal function as compared to placebo in patients hospitalized with acute decompensated heart failure undergoing aggressive intravenous diuretic therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 67 (actual)
- First submitted
- 1 Apr 2020
- Start date
- 20 May 2020
- Primary completion date
- 1 Jun 2022
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Heart failure
- NCT number
- NCT04334668
What you commit to
- Study type: Interventional
- Participants enrolled: 67
- From 20 May 2020 to the primary completion date, 1 Jun 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Admission with intention to transplant or implant permanent Ventricular Assistive Device
- Use of renal replacement therapy at time of enrollment
Other illness
- Active diagnosis of diabetes insipidus
- Presence of malabsorptive gastrointestinal disorder (Crohn's disease, short gut syndrome)
- A baseline estimated glomerular filtration rate \<15 mL/min/1.73m² according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the moment of inclusion
Lab values
- Serum sodium (Na+) level less than 120 or greater than 145.
- Current use of sodium chloride tablets
Other
- Average Systolic Blood Pressure \>180 mmHg or Diastolic Blood Pressure \>100 mmHg over past 24 hours.
- Anticipated length of stay less than 72 hours.
- Use of vasopressin antagonist
- Inability to tolerate oral diet or swallow pills
- The use of iodinated radiocontrast material in the past 72 hours or anticipated use of intravenous contrast during the current hospitalization
- Use of intravenous inotropes, vasopressors or vasodilators at enrollment
Who the study is looking for
- Age ≥ 18 years old AND
- Admitted to cardiology floor (non-ICU) with primary diagnosis of decompensated heart failure AND
- NT-proBNP \>1000 ng/L AND
- Initiation of continuous furosemide infusion at a rate of 10 mg/hr or higher
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.